Details of the Drug
General Information of Drug (ID: DMHBO17)
Drug Name |
4,6-dichloro-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4,6-Dichloroisatin; 18711-15-4; 4,6-Dichloro-1H-indole-2,3-dione; 4,6-DICHLOROINDOLINE-2,3-DIONE; 4,6-dichloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione,4,6-dichloro-; CGCVHJCZBIYRQC-UHFFFAOYSA-N; 4,6-dichloro-1H-benzo[d]azoline-2,3-dione; 4,6-dichlorisatin; NSC72897; AC1L5KVQ; AC1Q3MQL; Isatin-based compound, 50; SCHEMBL124586; CHEMBL385800; Jsp003834; BDBM22830; CTK4D9417; 4,6-dichloroindolin-2,3-dione; DTXSID60291058; 4,6-Dichloro-2,3-indolinedione; MolPort-001-969-148; ACT09176; ZINC1698777; ZERO/005650; KS-00000J1A
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 216.02 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||